José Halabe-Cherem
Mexican Social Security Institute
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by José Halabe-Cherem.
Angiology | 1998
Samuel Chacek; Julian MacGregor-Gooch; José Halabe-Cherem; Haiko Nellen-Hummel; Alfredo Quiñones-Galvan
Pyoderma gangrenosum is a rare cutaneous disorder frequently associated with systemic diseases. The authors report the case of a 28-year-old man with pyoderma gangrenosum and inferior cava vein syndrome due to thrombosis. The search for pyoderma gangrenosum-associated conditions (gastrointestinal, rheumatic, neoplasic, and infec tious diseases) was negative. A prolonged partial thromboplastin time and a positive test for circulating anticardiolipin antibodies strongly suggested the diagnosis of the antiphos pholipid syndrome. There are reports of at least three other cases of pyoderma gangrenosum associated with the antiphospholipid syndrome. This clinical case adds further evidence to the possible link between these disorders and warrants a search for anticardiolipin antibodies in patients with pyoderma gangrenosum.
Angiology | 1995
José Halabe-Cherem; Haiko Nellen-Hummel; Guillermo Flores-Padilla; Moisés Mercado-Atri; Javier Pizutto-Chavez
The authors present the case of a twenty-one-year-old woman with familial Mediter ranean fever who during her first pregnancy developed a primary antiphospholipid syn drome. This is an association not reported previously.
Archives of Medical Research | 2000
Antonio Palma-Aguirre; José Halabe-Cherem; Haiko Nellen-Hummel; Elsa Aburto-Mejı́a; Enrique Ibarra-Herrera; Héctor Ponce-Monter
BACKGROUND The use of protease inhibitors has revolutionized the treatment of HIV infection. These agents are well tolerated, although the Federal Drug Administration (FDA) has warned U.S. doctors that protease inhibitors may precipitate hyperglycemia and diabetes (DM), based on isolated reports from physicians. METHODS Sixty-one patients with HIV infection with criterion of non-DM from the onset of the protease inhibitor therapy participated in the study. Plasma glucose levels were obtained every month during a 6-month period, with a basal determination prior to protease inhibitor therapy. RESULTS All Mexican patients enrolled in this study had the same Hispanic-American ethnic origin. Four patients (6.55%) developed hyperglycemia related with saquinavir. One had family history of DM type II. These patients were controlled with diet. CONCLUSIONS Based on present data, we believe the benefits of these drugs to patients suffering from HIV infection outweigh the various risks of taking protease inhibitors. However, physicians who use these drugs have to be on the alert for hyperglycemia in the Mexican population, while patients should know the warning symptoms of hyperglycemia and diabetes.
JAMA Internal Medicine | 1998
Cristóbal Leonel Díaz-Sánchez; Alberto Lifshitz-Guinzberg; Gregorio Ignacio-Ibarra; José Halabe-Cherem; Alfredo Quiñones-Galvan
Revista médica del Instituto Mexicano del Seguro Social | 2007
Lorenza Martínez-Gallardo Prieto; Haiko Nellen-Hummel; Alicia Hamui-Sutton; José Halabe-Cherem
Gaceta Medica De Mexico | 1998
José Halabe-Cherem; Malagón J; Wacher-Rodarte N; Nellen-Hummel H; Talavera-Piña J
Revista médica del Instituto Mexicano del Seguro Social | 2009
Alicia Hamui-Sutton; Haiko Nellen-Hummel; Miguel Ángel Fernández-Ortega; José Halabe-Cherem
Cirugia Y Cirujanos | 2006
Lorenza Martínez Gallardo-Prieto; Haiko Nellen-Hummel; Alicia Hamui-Sutton; Jorge Alberto Castañón-González; Enrique Ibarra-Herrera; José Halabe-Cherem
Revista médica del Instituto Mexicano del Seguro Social | 2009
José Halabe-Cherem; Alicia Hamui-Sutton; Salomón Cohen-Cohen; Elisa Sacal-Dumani; Shuchleib-Cung A; Haiko Nellen-Hummel; Julia Rábago-Arredondo
Revista médica del Instituto Mexicano del Seguro Social | 2006
Gladys Patricia Agreda-Vásquez; María Eugenia Galván-Plata; Haiko Nellen-Hummel; José Halabe-Cherem